Abraxis BioScience

Ford Hutman Media Establishes Advisory Panel

Retrieved on: 
Wednesday, June 8, 2022
Consulting, Communications, Professional Services, Public Relations, Investor Relations, Kraft Foods, Bloomberg News, FHM, Marketing, LLC, Ford Motor Company, Scientific and Technical Advisory Panel, Business, Harvard University School of Mining and Practical Geology, Harvard Business School, Senior, Bloomberg Businessweek, The New York Times, Therapy, Growth, Public relations, Indiana University, San Francisco Chronicle, General Foods, Economics, Metabolism, HBO, Twitter, Industry, Department, Stanford University, Abraxis BioScience, Friedman, Financial adviser, Management, Illumina, Medicine

Ford Hutman Media (FHM), an industry-leading, life science-focused strategic communications firm, announced the establishment of the Ford Hutman Media Advisory Panel including the appointments of five industry experts that will serve as strategic advisors.

Key Points: 
  • Ford Hutman Media (FHM), an industry-leading, life science-focused strategic communications firm, announced the establishment of the Ford Hutman Media Advisory Panel including the appointments of five industry experts that will serve as strategic advisors.
  • Rachel Ford Hutman will serve as chair of the Advisory Panel.
  • The Advisory Panel includes:
    Dr. Alain Baron: Dr. Baron is a physician-scientist, experienced biotech chief executive officer, board member, strategic advisor and consultant.
  • Ford Hutman Media (FHM) was created to provide industry-leading communications strategies, media relations and thought leadership to elite biotech, digital health, diagnostics and medical technology companies.

Volta Labs to Unveil Digital Fluidics at AGBT

Retrieved on: 
Thursday, June 2, 2022
Science, Software, Other Science, Biotechnology, Hardware, Health, Technology, Genetics, Chemistry, Biology, Associate Director of National Intelligence and Chief Information Officer, CEO, Software, Broad Institute, Volta, Solution, Digital, Budget, Workflow, Technology, Laboratory, DNA, Industry, Abraxis BioScience, Apple IIe, Automation, Fine chemical, Labs

Volta Labs , a bioautomation company developing solutions to streamline the upstream workflows in genomic sequencing, today announced numerous advances in digital fluidics that will be presented at AGBT General Meeting.

Key Points: 
  • Volta Labs , a bioautomation company developing solutions to streamline the upstream workflows in genomic sequencing, today announced numerous advances in digital fluidics that will be presented at AGBT General Meeting.
  • We have been hard at work to develop bioautomation technology and we are excited to unveil the company and the technology at AGBT, said Udayan Umapathi, CEO at Volta Labs.
  • Volta Labs is building a sequencing technology agnostic platform that spans from the raw biological sample to sequenceable molecules.
  • Volta Labs approaches this challenge with a multidisciplinary solution that re-imagines fluidics and automation from the ground up.

LC Sciences' Microarray-Based Synthesis of Large Oligonucleotide Pools as a Source for Distinct, Non-Random NGS Barcodes

Retrieved on: 
Thursday, June 2, 2022
Scientific Reports, Research, Noise, Business, Engineering, NS, ONT, National university, UNR, Technology, DNA, PCR, Drug development, Oxford Nanopore Technologies, CONICET, Genomics, Hebrew University of Jerusalem, Abraxis BioScience, Proteomics, Oligonucleotide, Computer data storage, Fine chemical, Nature

HOUSTON, June 2, 2022 /PRNewswire-PRWeb/ -- Researchers have demonstrated that, despite the intrinsically low raw accuracy of long-read sequencing technologies, multiplex sequencing in these technologies can be improved to a read recovery rate and crosstalk rate similar to current high-accuracy short-read sequencing technologies using non-random error-correcting barcodes synthesized in massive parallel on a microarray.

Key Points: 
  • However, this emerging technology suffers from reduced raw accuracy when compared to current short-read sequencing technologies.
  • Random DNA barcodes have already been successfully used in high-accuracy short-read sequencing as unique molecular identifiers to filter out duplicate reads and PCR errors.
  • Error-correcting non-random DNA barcodes represents a possible solution to improve recovery in spite of the low raw accuracy of long-read sequencing.
  • However, the synthesis of such a large number of known sequences using traditional column-based synthesis methods is cost-prohibitive.

Komprise Automates Unstructured Data Discovery with Smart Data Workflows

Retrieved on: 
Thursday, May 19, 2022
API, AI, IOT, Information technology, Crash, GDPR, Abraxis BioScience, Industry, Time, Compliance, Mutation, Shredding (disassembling genomic data), Genomics, Machine learning, CEO, Data management, GLOBE, Medical device, Computer data storage, Feed manufacturing

CAMPBELL, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Komprise , the leader in analytics-driven unstructured data management and mobility, today announced Komprise Smart Data Workflows, a systematic process to discover relevant file and object data across cloud, edge and on-premises datacenters and feed data in native format to AI and machine learning (ML) tools and data lakes.

Key Points: 
  • CAMPBELL, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Komprise , the leader in analytics-driven unstructured data management and mobility, today announced Komprise Smart Data Workflows, a systematic process to discover relevant file and object data across cloud, edge and on-premises datacenters and feed data in native format to AI and machine learning (ML) tools and data lakes.
  • This creates an unstructured data blind spot, resulting in billions of dollars in missed big data opportunities.
  • Komprise Global File Index and Smart Data Workflows together reduce the time it takes to find, enrich and move the right unstructured data by up to 80%.
  • Whether its massive volumes of genomics data, surveillance data, IoT, GDPR or user shares across the enterprise, Komprise Smart Data Workflows orchestrate the information lifecycle of this data in the cloud to efficiently find, enrich and move the data you need for analytics projects, says Kumar Goswami, CEO of Komprise.

Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Company, Genentech, Patient, View, NASDAQ, Abraxis BioScience, TNBC, Bristol Myers Squibb, Conference, RCC, Nivolumab, Pharmaceutical industry, Kerosene, Infinity

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.

Key Points: 
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
  • Infinity Pharmaceuticals, Inc. (Infinity or the Company), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies.
  • MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022.
  • MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo (nivolumab) in I/O nave urothelial cancer.

Nanotechnology in the Medical Applications: The Global Market 2022

Retrieved on: 
Monday, May 16, 2022
ROW, Mark (given name), Company, Abbott, Medicine, Infection, Investment, Geography, Nano, Projection, CNS, Nanotechnology, Industry, Abraxis BioScience, Therapy, CAGR, Cancer, Positive economics, Nanomedicine, Cardiovascular disease, Pharmaceutical industry, Risk management

DUBLIN, May 16, 2022 /PRNewswire/ -- The "Nanotechnology in Medical Applications: The Global Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 16, 2022 /PRNewswire/ -- The "Nanotechnology in Medical Applications: The Global Market" report has been added to ResearchAndMarkets.com's offering.
  • Nano-enabled medical products began emerging on the market over a decade ago, and some have evolved as the best-sellers in their therapeutic categories.
  • It offers a detailed analysis of the market background, technological advancements, competitive environment, drivers and restraints, and market growth trends.
  • The report includes market projections through 2026, detailing the market share for nanomedicine based on therapeutic areas and geography.

Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint Pharmaceuticals and Farfield Scientific - ResearchAndMarkets.com

Retrieved on: 
Monday, May 9, 2022
Technology, Nanotechnology, ROW, Nanomedicine, Abraxis BioScience, Investment, Projection, Mark (given name), Abbott, CNS, Medicine, Company, Cardiovascular disease, Positive economics, Nanotechnology, Geography, Cancer, Therapy, Industry, Nano, CAGR, Infection, Medical device, Pharmaceutical industry, Risk management

The "Nanotechnology in Medical Applications: The Global Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nanotechnology in Medical Applications: The Global Market" report has been added to ResearchAndMarkets.com's offering.
  • Nano-enabled medical products began emerging on the market over a decade ago, and some have evolved as the best-sellers in their therapeutic categories.
  • The leading areas in which nanomedical products have made an impact are CNS diseases, cancer, cardiovascular disease, and infection control.
  • The report includes market projections through 2026, detailing the market share for nanomedicine based on therapeutic areas and geography.

PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows

Retrieved on: 
Monday, May 9, 2022
U.S. Securities and Exchange Commission, Sequel, Automation, NASDAQ, GLOBE, Â, Securities Exchange Act of 1934, Company, Research, Robotics, Security (finance), Apple IIe, Human, Abraxis BioScience, Adoption, High fidelity, Private Securities Litigation Reform Act, Infection, Solution, RBI, Technology, Microbiology, ILAC, Risk management, Medical imaging

Using technical information and feedback from PacBio, iLAC and RBI will work together to develop and validate automated high-throughput solutions on RBIs LabDroid robotic system for deployment at iLACs genomic services facility in Tsukuba, Japan.

Key Points: 
  • Using technical information and feedback from PacBio, iLAC and RBI will work together to develop and validate automated high-throughput solutions on RBIs LabDroid robotic system for deployment at iLACs genomic services facility in Tsukuba, Japan.
  • These automated workflows will support whole-genome sequencing, targeted sequencing and Iso-Seq, PacBios industry-leading isoform-resolution transcriptome application, on PacBios Sequel II and Sequel IIe platforms.
  • iLACs track record of success in offering highly innovative, advanced, and cost-effective fully automated sequencing workflows make them an ideal partner for PacBio.
  • We believe this collaboration, and the automated sequencing workflows that may result from it, could support broader adoption of long-read sequencing in the market.

PacBio to Participate in the BofA Securities 2022 Healthcare Conference

Retrieved on: 
Thursday, May 5, 2022
Infection, Conference, Webcast, Solution, Technology, Research, Microbiology, Bank of America, Abraxis BioScience, High fidelity, NASDAQ, GLOBE

MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Key Points: 
  • MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
  • PacBios management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time.
  • A replay of the webcast will be available for at least 30 days following the presentation.
  • PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.

PacBio Announces First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Computational biology, COVID-19, U.S. Securities and Exchange Commission, Sequel, Investment, Table, GAAP, EMEA, NASDAQ, GLOBE, RNA, Company, Securities Exchange Act of 1934, Broad Institute, Neurodevelopmental disorder, Broad, Apple IIe, Security (finance), Partnership, Methylation, Program, Hospital for Sick Children (Toronto), Hospital, High fidelity, Private Securities Litigation Reform Act, Income, Marketing, Intention, Infection, Lists of diseases, Solution, Technology, Research, Microbiology, Growth, KK, Video game, Bank, Antibiotics, Fine chemical, Risk management, Abraxis BioScience, Illumina

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022.

Key Points: 
  • MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022.
  • Operating expenses totaled $91.7 million for the first quarter of 2022, compared to $46.7 million for the first quarter of 2021.
  • Net loss for the first quarter of 2022 was $81.5 million, compared to a net loss of $87.4 million for the first quarter of 2021.
  • Non-GAAP net loss per share for the first quarter of 2022 was $0.37 compared to $0.18 for the first quarter of 2021.